- SOPHiA GENETICS ( NASDAQ: SOPH ) has entered a partnership with precision oncology company Boundless Bio to develop therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers .
- Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) as well as a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient's tumor sequencing data.
- SOPHiA ( SOPH ) said its ability to harmonize data derived from diverse genomic instruments combined with Boundless Bio's drug development capabilities can optimize patient selection and clinical trial design and support a network of hospitals and academic centers to deliver new treatment options for oncogene amplified cancers.
- SOPHiA ( SOPH ) also recently entered into an agreement with Memorial Sloan Kettering Cancer Center to allow its global network of healthcare providers access to MSK's proprietary tumor sequencing tests.
- Seeking Alpha's Quant Rating views SOPHiA ( SOPH ) as a hold with high marks for growth and valuation .
For further details see:
SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies